Breaking News Instant updates and real-time market news.

CRL

Charles River

$83.48

0.44 (0.53%)

, RHHBY

Roche

$30.56

0.073 (0.24%)

08:05
10/11/16
10/11
08:05
10/11/16
08:05

Charles River announces extension of integrated discovery program with Genentech

Charles River Laboratories International (CRL) announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group (RHHBY). Through this alliance, Charles River provides Genentech early discovery services, including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design, to help identify promising candidates for preclinical development. Charles River and Genentech have engaged in an ongoing program since 2005, with the latest extension providing a three-year continuation. The program began with a single project involving medicinal chemistry, and has evolved over the past 11 years to a multi-disciplinary collaboration drawing on Charles River's researchers in chemistry, biology and pharmacology.

CRL

Charles River

$83.48

0.44 (0.53%)

RHHBY

Roche

$30.56

0.073 (0.24%)

  • 19

    Oct

  • 02

    Nov

  • 06

    Nov

  • 10

    Nov

CRL Charles River
$83.48

0.44 (0.53%)

09/06/16
UBSW
09/06/16
DOWNGRADE
Target $78
UBSW
Sell
Charles River downgraded to Sell from Neutral at UBS
UBS analyst Jonathan Groberg downgraded Charles River Laboratories to Sell saying 2016 looks like a "peak organic growth year" for the company. The analyst sees a "number of risks" to 2017 consensus estimates. He lowered his price target for the shares to $78 from $83.
08/18/16
RHCO
08/18/16
NO CHANGE
RHCO
Charles River reported 'strong' results, says SunTrust
SunTrust analyst Sandy Draper says that Charles River reported "strong" results, and he says that the company should benefit from synergies from its acquisition of Wil Research in the next two to three quarters. Draper keeps a Buy rating on the stock.
08/04/16
BARD
08/04/16
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $92 at Baird
Baird raised its price target on Charles River Labs to $100 from $92 following solid Q2 results. The firm believes the company's outlook is bright and its performance drivers were balanced, noting also that guidance was raised. Baird reiterated its Outperform rating on Charles River shares.
06/20/16
FBCO
06/20/16
INITIATION
Target $84
FBCO
Neutral
Charles River initiated with a Neutral at Credit Suisse
Target $84.
RHHBY Roche
$30.56

0.073 (0.24%)

09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.

TODAY'S FREE FLY STORIES

EIX

Edison International

$69.44

-0.17 (-0.24%)

18:42
12/08/16
12/08
18:42
12/08/16
18:42
Hot Stocks
Edison International raises annual dividend 13% to $2.17 per share »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.87

0.0001 (0.01%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Earnings
Breaking Earnings news story on PolyMet Mining »

PolyMet Mining reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$18.38

0.18 (0.99%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Hot Stocks
Match Group launches 'Swipe Ventures,' says Tinder CEO to step down »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

18:18
12/08/16
12/08
18:18
12/08/16
18:18
Hot Stocks
Biogen to present aducanumab Phase 1b data at CTAD meeting »

Biogen announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

HIVE

Aerohive

$5.41

0.18 (3.44%)

18:17
12/08/16
12/08
18:17
12/08/16
18:17
Hot Stocks
Discovery Group reports 9.1% stake in Aerohive Networks, sends letter to board »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

, ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

18:05
12/08/16
12/08
18:05
12/08/16
18:05
Periodicals
Outrigger Energy nears sale to midstream services provider, Forbes says »

Private-equity backed…

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

TRGP

Targa Resources

$54.20

0.38 (0.71%)

ETP

Energy Transfer Partners

$35.13

0.55 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$78.65

0.96 (1.24%)

18:02
12/08/16
12/08
18:02
12/08/16
18:02
Hot Stocks
Post Holdings settles egg antitrust class action claims »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENZN

Enzon

$0.44

-0.0027 (-0.62%)

17:54
12/08/16
12/08
17:54
12/08/16
17:54
Hot Stocks
Icahn says enters standstill pact with Enzon »

In an amended filing on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$52.27

0.15 (0.29%)

17:53
12/08/16
12/08
17:53
12/08/16
17:53
Hot Stocks
Leidos awarded $350M government contract »

Leidos, Reston, Virginia,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:50
12/08/16
12/08
17:50
12/08/16
17:50
Hot Stocks
Dominion Diamond sees FY17 production at Ekati diamond mine 4.5M carats »

Sees FY17 Ekati diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FNSR

Finisar

$34.13

1.89 (5.86%)

, AVGO

Broadcom

$170.71

2.16 (1.28%)

17:49
12/08/16
12/08
17:49
12/08/16
17:49
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

FNSR

Finisar

$34.13

1.89 (5.86%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

XTLY

Xactly

$14.35

0.35 (2.50%)

RH

Restoration Hardware

$38.99

1.05 (2.77%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

NCS

NCI Building

$17.85

0.6 (3.48%)

FRED

Fred's

$10.84

0.15 (1.40%)

USAC

USA Compression

$18.01

-0.14 (-0.77%)

FRO

Frontline

$7.71

0.37 (5.04%)

WSM

Williams-Sonoma

$56.90

0.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

, ANTM

Anthem

$146.61

1.41 (0.97%)

17:48
12/08/16
12/08
17:48
12/08/16
17:48
Hot Stocks
Citron's Andrew Left: 'By no means' calling Express Scripts a fraud or zero »

Speaking in a CNBC…

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

ANTM

Anthem

$146.61

1.41 (0.97%)

CVS

CVS Health

$78.11

-2.42 (-3.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:45
12/08/16
12/08
17:45
12/08/16
17:45
Earnings
Dominion Diamond reports Q3 EPS 34c with items, consensus (32c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FRO

Frontline

$7.71

0.37 (5.04%)

17:44
12/08/16
12/08
17:44
12/08/16
17:44
Syndicate
Frontline announces contemplated offering of $100M of common stock »

Frontline has mandated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRED

Fred's

$10.84

0.15 (1.40%)

17:42
12/08/16
12/08
17:42
12/08/16
17:42
Hot Stocks
Fred's says won't take questions due to pending transaction »

On its quarterly earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

17:35
12/08/16
12/08
17:35
12/08/16
17:35
Hot Stocks
Breaking Hot Stocks news story on Express Scripts »

Citron's Left: By no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNST

Renasant

$44.18

0.75 (1.73%)

, HBOS

Heritage Financial

17:34
12/08/16
12/08
17:34
12/08/16
17:34
Hot Stocks
Renasant announces early termination of all FDIC loss share agreements »

Renasant Corporation…

RNST

Renasant

$44.18

0.75 (1.73%)

HBOS

Heritage Financial

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COTV

Cotiviti Holdings

$34.41

0.88 (2.62%)

17:34
12/08/16
12/08
17:34
12/08/16
17:34
Syndicate
Cotiviti Holdings requests withdrawal of registration statement »

The company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

17:33
12/08/16
12/08
17:33
12/08/16
17:33
Hot Stocks
Breaking Hot Stocks news story on Galapagos NV »

Galapagos: 1st patient…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ARNC

Arconic

$20.91

0.03 (0.14%)

17:32
12/08/16
12/08
17:32
12/08/16
17:32
Hot Stocks
Breaking Hot Stocks news story on Arconic »

Elliot Associates raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

17:30
12/08/16
12/08
17:30
12/08/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Express Scripts »

Citron's Left on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBS

Emergent BioSolutions

$27.22

0.7 (2.64%)

17:28
12/08/16
12/08
17:28
12/08/16
17:28
Earnings
Emergent BioSolutions sees FY16 continuing ops revenue 465M-$485M »

Sees FY16 total revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.70

0.4 (2.45%)

17:26
12/08/16
12/08
17:26
12/08/16
17:26
Hot Stocks
Steelcase says Q3 orders in Americas grew about 3.5% »

Orders in the Americas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

SCS

Steelcase

$16.70

0.4 (2.45%)

17:24
12/08/16
12/08
17:24
12/08/16
17:24
Earnings
Steelcase reports preliminary Q3 EPS 34c, consensus 34c »

Reports preliminary Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

MVIS

MicroVision

$1.33

-0.07 (-5.00%)

17:23
12/08/16
12/08
17:23
12/08/16
17:23
Syndicate
MicroVision announces offering of common stock, no amount given »

Ladenburg Thalmann &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.